To understand the focus of startup Insamo Inc., one need look no further than its name, which co-founder and CEO Timothy Craven described as “portmanteau of ‘internally satisfied molecules,’” highlighting its efforts to create orally administered and membrane-permeable cyclic peptides across a range of disease areas.
BERKELEY, Calif. (BUSINESS WIRE) Insamo, a biotechnology company pioneering the discovery of membrane-permeable and orally available cyclic-peptides, today announced $12 million in seed capital from Playground Global, venBio, and MRL Ventures Fund (MRLV). MRLV is a corporate venture arm of Merck & Co., Inc which i.
JELD-WEN (NYSE:JELD – Get Free Report) had its price objective upped by B. Riley from $18.00 to $19.00 in a note issued to investors on Thursday, MarketBeat reports. The brokerage currently has a “neutral” rating on the stock. B. Riley’s price target points to a potential upside of 16.07% from the company’s previous close. B. […]
JELD-WEN (NYSE:JELD – Free Report) had its target price raised by Royal Bank of Canada from $12.00 to $13.00 in a report released on Wednesday morning, Benzinga reports. They currently have an underperform rating on the stock. JELD has been the topic of a number of other research reports. Stifel Nicolaus boosted their target price […]
JELD-WEN (NYSE:JELD – Get Free Report) issued its earnings results on Monday. The company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.33 by $0.11, Briefing.com reports. JELD-WEN had a return on equity of 25.42% and a net margin of 1.18%. The company had revenue of $1.13 billion during the quarter, compared […]